Trial Profile
Randomised phase II trial of cediranib (AZD2171) vs. placebo in addition to cisplatin/gemcitabine chemotherapy for patients with advanced biliary tract cancers.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Dec 2023
Price :
$35
*
At a glance
- Drugs Cediranib (Primary) ; Cisplatin; Gemcitabine
- Indications Biliary cancer; Carcinoma; Cholangiocarcinoma; Gallbladder cancer
- Focus Therapeutic Use
- Acronyms ABC-03
- 24 Oct 2023 Results of post hoc analysis (n=534 from ABC-01, 02 and 03 study) assessing reference survival data for patients with advanced eCCA treated with first-line cisplatin-gemcitabine (CisGem) chemotherapy within the prospective, randomised Advanced Biliary tract Cancer studies presented at the 48th European Society for Medical Oncology Congress
- 31 Mar 2022 Status changed from discontinued to completed.
- 25 Jan 2020 Results (N=994), post hoc analysis evaluated differences by sex in the frequency of adverse events and overall survival and its impact on progression-free survival /recurrence-free survival in biliary tract cancer, presented at the 2020 Gastrointestinal Cancers Symposium